EBOS Group (EBO.NZ) Stock Price
EBOS Group Price
Over the last 19 years EBOS Group grew revenue by 21.7% annually, reaching 10.38 B AUD. Earnings per share have grown at 8.9% per year over the last 19 years. For EBOS Group, the net margin of 1.7% is broadly stable versus 1.9% a few years ago. At today's price the dividend yield works out to roughly 8.85%. The payout ratio is around 111% of earnings. The dividend has grown at 7.8% per year over the past 19 years. The consensus 12-month price target for EBOS Group is 30.68 AUD, about 100.9% above where the stock trades today. Of 13 analysts, 10 rate the stock a buy — an overall Buy consensus.
EBOS Group stock price
EBOS Group business model & stock analysis
Frequently asked questions about EBOS Group
The business model of EBOS Group Ltd revolves around its position as a leading distributor of healthcare, laboratory, and pharmaceutical products. EBOS Group Ltd operates through two segments: Healthcare and Animal Care. The Healthcare segment supplies a broad range of medical products to public and private hospitals, pharmacies, and healthcare providers. The Animal Care segment focuses on providing veterinary products and services to veterinarians, farmers, and other animal healthcare professionals. With its robust distribution network and comprehensive product portfolio, EBOS Group Ltd strives to enhance healthcare outcomes and deliver value to its customers in the healthcare and animal care sectors.
EBOS Group Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of EBOS Group Ltd in the market include companies such as Sigma Healthcare Ltd, Australian Pharmaceutical Industries Limited (API), and New Zealand Pharmaceuticals Limited.
EBOS Group Ltd is a leading healthcare and animal care company based in New Zealand and Australia. With a rich history dating back to 1922, EBOS has grown to become a highly reputable player in the industry. Originally established as a pharmaceutical wholesaler, the company expanded its focus to healthcare and animal care through strategic acquisitions and partnerships. Today, EBOS Group Ltd operates across numerous sectors, including medical, dental, hospital, and retail pharmacy, as well as animal care and pet supplies. The company's commitment to delivering innovative solutions, along with its extensive network of partners and customer-centric approach, has contributed to its continued success and growth.
EBOS Group Ltd, a leading provider of healthcare and animal care products, has achieved several significant milestones. Firstly, the company expanded its operations internationally, establishing a strong presence in Australia and New Zealand. Secondly, EBOS made strategic acquisitions, including those of Symbion and Terry White Group, which further strengthened its market position. Additionally, EBOS achieved consistent revenue growth year on year, demonstrating its ability to deliver value to shareholders. Moreover, the company was recognized for its excellence through numerous awards, such as the Deloitte Top 200 Company of the Year. Overall, EBOS Group Ltd has successfully grown its business, expanded its reach, and gained industry recognition, solidifying its position in the market.
EBOS Group Ltd is primarily present in Australia and New Zealand.
EBOS Group Ltd represents values of integrity, collaboration, and excellence in its corporate philosophy. As a leading Australasian distributor of healthcare, medical, and pharmaceutical products, EBOS Group is committed to delivering high-quality solutions and services to its customers. The company's strong emphasis on ethical business practices and customer satisfaction has positioned it as a trusted partner in the healthcare industry. With a focus on continuous improvement and innovation, EBOS Group strives to enhance the well-being of individuals and communities through its diverse range of products and services.
Analysts currently set an average price target of 29.17 AUD for the EBOS Group stock (median: 30.68 AUD), implying +91.0 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the EBOS Group stock: 11 recommend buying, 1 holding and 1 selling.
Converted at the current exchange rate, the EBOS Group share trades at 9.48 EUR (15.28 AUD).
The EBOS Group share (EBO.NZ) is listed on 3 stock exchanges, including: ASX (EBO.AX), Frankfurt (EJG.F).
The EBOS Group Limited is a leading distributor of medical and pharmaceutical products in Australia, New Zealand, and Asia. Their business model is based on supplying products to medical facilities, pharmacies, and healthcare providers. The company operates in various sectors, including Healthcare, Animal Care, and Scientific. In the Healthcare sector, the EBOS Group is an important supplier of medical devices and consumables. They offer a wide range of products, ranging from surgical instruments and diagnostic devices to incontinence products and bandages. In the Animal Care sector, EBOS holds an extensive product list of veterinary medicines and supplies. The EBOS Group is one of the largest suppliers of animal medicines in Australia and New Zealand. The company works closely with veterinarians and professionals in animal health to ensure the best possible fulfillment of the needs of pets and livestock. In the Scientific sector, EBOS trades in laboratory equipment, chemicals, and other scientific products. The company also provides services such as calibration, repair, and maintenance of laboratory equipment. The EBOS Group aims to provide its customers with the highest quality and most innovative products and services. The company holds a wide range of products and brands in stock, including its own brands and established brands such as Johnson & Johnson and Roche. The business model of the EBOS Group is based on providing products and services that meet the needs of its customers. The company has established a network of distribution centers throughout Australia, New Zealand, and Asia to ensure that its customers are supplied quickly and effectively. The EBOS Group also has a strong online presence to enable its customers to easily purchase and access their products. The company also utilizes advanced IT systems and technologies to optimize the ordering and delivery process and ensure fast and reliable product delivery. Overall, the business model of the EBOS Group offers a wide range of high-quality products and services for diverse customer needs. The company is well positioned to leverage growth in the Healthcare, Animal Care, and Scientific sectors in Australia, New Zealand, and Asia, and strengthen its position as a leading company in the medical and pharmaceutical industry. Answer: The EBOS Group Limited is a leading distributor of medical and pharmaceutical products in Australia, New Zealand, and Asia. They provide products to medical facilities, pharmacies, and healthcare providers, and operate in the Healthcare, Animal Care, and Scientific sectors. They offer a wide range of products and brands, have a strong online presence, and utilize advanced technology to optimize the ordering and delivery process. The EBOS Group aims to provide high-quality products and services and is well positioned for growth in the industry.
The revenue of EBOS Group is 10.38 B AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of EBOS Group is 173.31 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of EBOS Group is currently 18.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the EBOS Group stock.
The price-to-sales ratio (P/S) of EBOS Group is currently 0.31. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the EBOS Group stock.
The Eulerpool Quality Score for EBOS Group is 3/10.
The ISIN of EBOS Group is NZEBOE0001S6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of EBOS Group is 724635. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of EBOS Group is EBO.NZ. The ticker symbol is used to trade EBOS Group shares on the stock exchange.
EBOS Group stock
All fundamentals and in-depth analysis of EBOS Group
Our stock analysis for EBOS Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EBOS Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.